Multiple Sclerosis Journal




One-year access to more than 500 world journals available in the system
    http://medilib.ir
  • Duration of Time : 365 Day
  • Price : 300$
  • Special Price : 100$
Order

Generic MS medications: Reducing costs without compromising safety

Emily M Schorrand Peter A Calabresi

doi : 10.1177/13524585221135129

Buy The Package and View The Article Online


Thematic analysis of multiple sclerosis research by enhanced strategic diagram

Nazlahshaniza Shafin, Che Aishah Nazariah Ismail, Mohd Zulkifli Mustafa, Nurhafizah Ghani,Asma Hayati Ahmad, Zahiruddin Othman, Adi Wijaya and Rahimah Zakaria

doi : 10.1177/13524585221075542

Recent interest in multiple sclerosis research warrants literature analysis to evaluate the current state of the discipline and new research domains. This bibliometric review summarised the research trends and analysed research areas in multiple sclerosis over the last decade. The documents containing the term ‘multiple sclerosis’ in the article title were retrieved from the Scopus database.

Buy The Package and View The Article Online


Artificial intelligence will change MS care within the next 10 years: Yes

Stijn Denissenand Guy Nagels

doi : 10.1177/13524585221130421

Buy The Package and View The Article Online


Artificial intelligence will change MS care within the next 10 years: No

Maarten De Vos and Jeroen Van Schependom

doi : 10.1177/13524585221125376

Buy The Package and View The Article Online


Artificial intelligence will change MS care within the next 10 years: Commentary

Luigi Lavorgna and Simona Bonavita

doi : 10.1177/13524585221133537

Buy The Package and View The Article Online


Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations

Wallace J Brownlee, Christian Wolf, Hans-Peter Hartung, Theo Dingermann, Nadia Anshasi,Richard AC Clark, Maria Trojano, Krzysztof Selmaj, Bernard MJ Uitdehaag, Carmen TurJens Wuerfel, Gabriele Dallmann, Julian Witte, Martina Sintzel, Olga Bobrovnikovaand Jeffrey A Cohen

doi : 10.1177/13524585221116269

As patents for multiple sclerosis (MS) therapies expire, follow-on disease-modifying treatments (FO-DMTs) become available at reduced cost. Concerns exist that cheaper FO-DMTs are used simply to reduce healthcare costs. However, the well-being of people with MS should take priority.

Buy The Package and View The Article Online


Changes in prognosis of the Danish multiple sclerosis population over time

Melinda Magyari, Hanna Joensen, Tine Iskov KoppLuigi Pontieriand Nils Koch-Henriksen

doi : 10.1177/13524585221110582

The course of multiple sclerosis (MS) appears to be milder in recent decades.

Buy The Package and View The Article Online


Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis

Amjad I Altokhis, Aimee M Hibbert, Christopher M AllenOlivier Mougin, Abdulmajeed Alotaibi, Su-Yin Lim, Cris S ConstantinescuRasha Abdel-Fahimand Nikos Evangelou

doi : 10.1177/13524585221114750

Iron rims (IRs) surrounding white matter lesions (WMLs) are suggested to predict a more severe disease course. Only small longitudinal cohorts of patients with and without iron rim lesions (IRLs) have been reported so far.

Buy The Package and View The Article Online


Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis

Isobel Meaton*, Amjad Altokhis*, Christopher Martin Allen,Margareta A Clarke, Tim Sinnecker, Dominik Meier, Christian Enzinger,Massimiliano Calabrese, Nicola De Stefano, Alain Pitiot, Antonio Giorgio,Menno M Schoonheim, Friedemann Paul, Mikolaj A Pawlak, Reinhold Schmidt,Cristina Granziera, Ludwig Kappos, Xavier Montalban, Àlex Rovira, Jens Wuerfeland Nikos Evangelou*; on behalf of the MAGNIMS study group

doi : 10.1177/13524585221118677

2212Isobel Meaton*, Amjad Altokhis*, Christopher Martin Allen,Margareta A Clarke, Tim Sinnecker, Dominik Meier, Christian Enzinger,Massimiliano Calabrese, Nicola De Stefano, Alain Pitiot, Antonio Giorgio,Menno M Schoonheim, Friedemann Paul, Mikolaj A Pawlak, Reinhold Schmidt,Cristina Granziera, Ludwig Kappos, Xavier Montalban, Àlex Rovira, Jens Wuerfeland Nikos Evangelou*; on behalf of the MAGNIMS study group

Buy The Package and View The Article Online


Relapsing antibody-negative patients with features of neuromyelitis optica spectrum disorders: Differences in N-acetylaspartate level in the cervical spinal cord indicate distinct underlying processes

Bartosz Kossowski, Yazhuo Kong, Elżbieta Klimiec-Moskal, Uzay Emir,Jacqueline Palace and Maciej Juryńczyk

doi : 10.1177/13524585221115304

Due to lack of biomarkers, antibody-negative patients with features of neuromyelitis optica spectrum disorders (NMOSD) are among the most challenging to diagnose and treat. Using unsupervised clustering, we recently identified ‘MS-like’, ‘spinal MS-like’, ‘classic NMOSD-like’ and ‘NMOSD-like with brain involvement’ subgroups in this cohort.

Buy The Package and View The Article Online


Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis

Zoë YGJ van Lierop, Samantha Noteboom*, Martijn D Steenwijk,Maureen van Dam, Alyssa A Toorop, Zoé LE van Kempen, Bastiaan Moraal,Frederik Barkhof, Bernard MJ Uitdehaag, Menno M SchoonheimCharlotte E Teunissen and Joep Killestein

doi : 10.1177/13524585221118676

Despite highly effective treatment strategies for patients with relapsing-remitting multiple sclerosis (RRMS), long-term neurodegeneration and disease progression are often considerable. Accurate blood-based biomarkers that predict long-term neurodegeneration are lacking.

Buy The Package and View The Article Online


Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register

Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Francesco Patti, Marco Onofrj,Vincenzo Brescia Morra, Mauro Zaffaroni, Carlo Pozzilli, Eleonora Cocco, Patrizia Sola,Giuseppe Salemi, Matilde Inglese, Roberto Bergamaschi, Claudio Gasperini, Antonella Conte,Marco Salvetti, Giacomo Lus, Giorgia Teresa Maniscalco, Rocco Totaro, Marika Vianello,Franco Granella, Elisabetta Ferraro, Umberto Aguglia, Maurizia Gatto, Francesca Sangalli,Clara Grazia Chisari, Giovanna De Luca, Antonio Carotenuto, Damiano BaronciniDelia Colombo, Mihaela Nica, Damiano Paolicelli, Giancarlo Comi, Massimo FilippiMaria Pia Amatoand Maria Trojano; on behalf of the Italian MS Register

doi : 10.1177/13524585221114007

Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available.

Buy The Package and View The Article Online


Machine learning classification of multiple sclerosis in children using optical coherence tomography

Beyza Ciftci Kavaklioglu, Lauren Erdman, Anna Goldenberg, Can Kavaklioglu,Cara Alexander, Hannah M Oppermann, Amish Patel, Soaad Hossain, Tara Berenbaum,Olivia Yau, Carmen Yea, Mina Ly, Fiona Costello, Jean K Mah, Arun Reginald,Brenda Banwell, Giulia Longoni and E Ann Yeh

doi : 10.1177/13524585221112605

In children, multiple sclerosis (MS) is the ultimate diagnosis in only 1/5 to 1/3 of cases after a first episode of central nervous system (CNS) demyelination. As the visual pathway is frequently affected in MS and other CNS demyelinating disorders (DDs), structural retinal imaging such as optical coherence tomography (OCT) can be used to differentiate MS.

Buy The Package and View The Article Online


Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis

Ih Chang*, Ludwig Kappos, Gavin Giovannoni, Peter A Calabresi, Alfred SandrockWenting Cheng, Shan Xiao*, Katherine Riester, Shibeshih Belachew, Aaron Deykinand Bing Zhu

doi : 10.1177/13524585221114997

Overall Disability Response Score (ODRS) is a composite endpoint including Expanded Disability Status Scale, Timed 25-foot Walk, and 9-Hole Peg Test, designed to quantify both disability improvement and worsening in multiple sclerosis (MS).

Buy The Package and View The Article Online


Measuring coping in multiple sclerosis: The Coping Index-MS

Carolyn A Young, Roger J Mills, Dawn Langdon, David J Rog, Basil Sharrack,Seema Kalra, Tahir Majeed, David Footit, Tim Harrower, Richard S NicholasHelen L Ford, John Woolmore, Clare Johnstone, John Thorpe, David Paling,Cathy Ellis, C Oliver Hanneman and Alan Tennant

doi : 10.1177/13524585221114004

Coping in multiple sclerosis (MS) refers to cognitive and behavioural efforts to manage stresses imposed by the illness. Existing generic and disease-specific coping scales do not meet modern guidelines for scale development and cannot produce interval-level metrics to allow for change scores.

Buy The Package and View The Article Online


The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis

Sarah Alexander, Marie Braisher, Carmen Tur and Jeremy Chataway

doi : 10.1177/13524585221124043

Clinical studies in multiple sclerosis (MS) often require accurate measurement of walking distance. Utilisation of electronic devices could theoretically improve this. Mobile devices have the potential to continuously monitor health by collecting movement data. Popular fitness trackers record steps taken and distance travelled, typically using a fixed-stride length. However, applications using fixed-stride length may be less accurate in those with altered gait patterns. While useful for everyday purposes, medical monitoring requires greater accuracy.

Buy The Package and View The Article Online


Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions

Philipp Eisele, Matthias Wittayer, Claudia E Weber,Michael Platten, Lucas Schirmerand Achim Gass

doi : 10.1177/13524585221106338

We investigated the impact of disease-modifying therapies (DMTs) on the evolving tissue damage in iron rim multiple sclerosis lesions using a novel post-processing magnetic resonance imaging (MRI) approach, the T1/T2 ratio. In this study, on baseline and 1-year follow-up, T1/T2 ratios of iron rim lesions (IRLs) in patients starting DMT (dimethyl fumarate, fingolimod, ocrelizumab) did not statistically differ compared to patients without DMT. At the second follow-up, T1/T2 ratios were significantly lower in IRLs in patients without DMT (p = 0.002), suggesting that DMTs have a beneficial delayed effect on lesion evolution and tissue matrix damage in IRLs.

Buy The Package and View The Article Online


EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold

Stephen C Krieger, Ali Antoine and James F Sumowski

doi : 10.1177/13524585221108297

Little to no above-threshold deficits may be evident in early multiple sclerosis (MS). The Expanded Disability Status Scale (EDSS) is a standard measure of neurologic function, with an EDSS score of 0 defined as “neurologically normal.� The topographical model of MS proposes that sub-threshold disease is compensated for by functional reserve. In this short report, we found that physically high-challenge measures of balance and upper extremity coordination reveal sub-threshold deficits in patients with EDSS score of 0 compared with healthy controls. Challenge task performance was correlated with imaging markers of both lesional burden of disease and a volumetric measure of brain reserve.

Buy The Package and View The Article Online


Do you want to add Medilib to your home screen?